SCHEMBL19968879

SCHEMBL19968879

CC(C)COc1ccccc1-c1nc(NS(=O)(=O)c2cccc(N3CCC(C)CC3)n2)ccc1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 6/20 0.37
SCN8A Q9UQD0 5/20 0.37
TTR P02766 1/20 0.35
SCN9A Q15858 3/20 0.35
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
HTR1A P08908 2/20 0.33
HTR7 P34969 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HSD11B1 P28845 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
SCN5A Q14524 1/20 0.32
TP53 P04637 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19968878 0.91 SCN1A (0.38) SCN1ASCN8ATTRSCN9AMAPT
SCHEMBL19968881 0.88 HSD11B1 (0.38) SCN1ASCN8AHTR1AHTR7GAA
SCHEMBL19925059 0.87 PRKCA (0.33) SCN1ASCN8ATTRSCN9A
SCHEMBL19925823 0.83 SCN1A (0.32) SCN1ASCN8ATTRSCN9ASCN5A
SCHEMBL19925824 0.83 SCN1A (0.32) SCN1ASCN8ATTRSCN9ASCN5A
SCHEMBL19968882 0.83 SCN1A (0.37) SCN1ASCN8ASCN9AGAAKDM4E
SCHEMBL19968873 0.82 SCN9A (0.36) SCN1ASCN8ASCN9AMAPK13MAPK12
SCHEMBL19968816 0.82 SCN9A (0.36) SCN1ASCN8ASCN9AMAPK13MAPK12
SCHEMBL19968890 0.80 HMOX1 (0.37) SCN1ASCN8AMAPTMAPK1L3MBTL1
SCHEMBL19968884 0.79 ALDH1A1 (0.39) SCN1ASCN8ASCN9AHTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 SCN1A 32/4885SCN8A 450/4885TTR 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.